Recent Articles

• 
  Samsung Bioepis

  Samsung Bioepis Makes Big Bet on Obesity Drug

  Kim Kyung-ah, President of Samsung Bioepis (center), Hong Sung-won, Executive Vice President (left, CEO of Epis Nexlab), and Lee Hee-yong, CEO of G2GBIO, sign an agreement for joint development of new biological drugs and a technology platform and pose for a commemorative photo. Provided by Samsung

  2026.03.16
• 
  Global Expansion

  Celltrion Cancer Drug Keeps Japan Lead; New Launch

  Celltrion announced on the 16th that its oncology biosimilar products are continuing to hold the No. 1 market share in Japan.According to pharmaceutical market research firm IQVIA and local data, as of December last year, the market share in Japan of metastatic colorectal cancer and breast cancer tr

  2026.03.16
• 
  Biopharma

  DongKook Pharma Shifts From Drugmaker to Healthcare Firm

  DongKook Pharmaceutical headquarters DongKook Pharmaceutical’s business structure has been changing in recent years. The company has long been known as a pharmaceutical firm centered on over-the-counter (OTC) brands such as Insadol and Madecassol, but it has recently begun to parallelly operate heal

  2026.03.13
• 
  Celltrion

  US Biosimilar Rule Easing Seen Boosting Celltrion

  Celltrion announced on the 13th that it will immediately reflect global regulators’ relaxed policies on biosimilar development in its ongoing pipeline, aiming to reduce development costs and shorten timelines.The U.S. Food and Drug Administration (FDA) recently released the fourth revised draft of i

  2026.03.13
• 
  AI Healthcare

  Daewoong Pharma: MobiCare Wearable ECG Enables Early AF Detection

  Medical staff at the Gyeongnam branch of the Korea Association of Health Promotion apply the wearable electrocardiogram device “mobiCARE” to a patient. Daewoong Pharmaceutical Daewoong Pharmaceutical announced on the 12th that its wearable electrocardiogram (ECG) testing solution “mobiCARE” has succ

  2026.03.12
• 
  Biopharma

  Alteogen Wins US Patent for Keytruda, Qurex Formulation

  Alteogen headquarters and research center Bioplatform company Alteogen announced on the 12th that it has registered with the United States Patent and Trademark Office (USPTO) a composition patent related to the subcutaneous formulation of Keytruda that combines its Hybrozyme platform-based ALT-B4 (i

  2026.03.12
• 
  Global Expansion

  Korean United Pharma Expands in Mongolia With Cancer Drugs

  Korea United Pharm is accelerating efforts to expand its market share in Mongolia by broadening contact points with local partners. The company announced on the 12th that it had invited GanEm Pharma, a Mongolian distribution company, on the 9th to discuss business strategies for boosting exports. Th

  2026.03.12
• 
  Medical / Research

  Kimchi Probiotics Help Expel Gut Microplastics

  Newsis Experimental results have shown that lactic acid bacteria derived from kimchi may promote the excretion of microplastics from the body. On the 11th, the research team of Dr. Lee Se-hee and Dr. Won Tae-woong at the World Institute of Kimchi announced that they had confirmed that the lactic aci

  2026.03.11
• 
  Biopharma

  Pharmainnovation, Caerance, Daoncare Sign Natural Product MOU

  Photo courtesy of Pharmainnovation Pharmaceutical OTM specialist Pharmainnovation Co., Ltd. announced that it has signed a memorandum of understanding (MOU) for cooperation in the development and commercialization of natural-substance-based products with healthcare platform specialist Carelance Co.,

  2026.03.11
• 
  Medical / Research

  IBS Team Uncovers Neuron-Astrocyte Mechanism in Brain Development

  The Institute for Basic Science (IBS) announced on the 10th that a research team led by Chang-Jin Lee, Director of the Center for Cognition and Sociality, and Research Fellow Sung-Ho Hong has identified the mechanism by which star-shaped non-neuronal cells called astrocytes enable complex and precis

  2026.03.11